​

Cogent Biosciences (COGT) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Cogent Biosciences Revenue Highlights

00

Main Segment (Y)

Preclinical Research And Clinical Development

Main Geography (Y)

Preclinical Research And Clinical Development

Cogent Biosciences Revenue by Period

Cogent Biosciences Revenue by Year

DateRevenueChange
2024-12-31-100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31--100.00%
2020-12-31$7.87M-65.02%
2019-12-31$22.50M131.14%
2018-12-31$9.73M16.44%
2017-12-31$8.36M31.55%
2016-12-31$6.36M112.83%
2015-12-31$2.99M-

Cogent Biosciences generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Cogent Biosciences Revenue by Quarter

DateRevenueChange
2025-06-30-100.00%
2025-03-31--100.00%
2024-12-31$4.29M100.00%
2024-09-30-100.00%
2024-06-30-100.00%
2024-03-31--100.00%
2023-12-31$5.59M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31--100.00%
2020-09-30$312.00K-40.91%
2020-06-30$528.00K-92.49%
2020-03-31$7.03M-54.01%
2019-12-31$15.29M1398.82%
2019-09-30$1.02M-67.50%
2019-06-30$3.14M2.78%
2019-03-31$3.05M-19.76%
2018-12-31$3.81M86.25%
2018-09-30$2.04M22.63%
2018-06-30$1.67M-24.95%
2018-03-31$2.22M4.57%
2017-12-31$2.12M-8.92%
2017-09-30$2.33M12.12%
2017-06-30$2.08M13.79%
2017-03-31$1.83M-

Cogent Biosciences generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.

Cogent Biosciences Revenue Breakdown

Cogent Biosciences Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 19Dec 18
Preclinical Research And Clinical Development$25.00M$25.00M

Cogent Biosciences's latest annual revenue breakdown by segment (product or service), as of Dec 19: Preclinical Research And Clinical Development (100.00%).

Cogent Biosciences Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 19Dec 18
Preclinical Research And Clinical Development$25.00M$25.00M

Cogent Biosciences's latest annual revenue breakdown by geography, as of Dec 19: Preclinical Research And Clinical Development (100.00%).

Cogent Biosciences Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
SRPTSarepta Therapeutics$1.90B$744.86M
GLPGGalapagos$239.70M$62.43M
OCULOcular Therapeutix$63.46M$13.39M
IBRXImmunityBio$14.74M$26.43M
MESOMesoblast$7.50M$1.69M
IDYAIDEAYA Biosciences$7.00M-
ETNB89bio--
COGTCogent Biosciences--
VERAVera Therapeutics--
DYNDyne Therapeutics--
DNLIDenali Therapeutics--

COGT Revenue FAQ

What is Cogent Biosciences’s yearly revenue?

Cogent Biosciences's yearly revenue for 2024 was $0, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. COGT's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is Cogent Biosciences’s quarterly revenue?

Cogent Biosciences's quarterly revenue for Q2 2025 was $0, a 100.00% increase from the previous quarter (Q1 2025), and a 0% increase year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $0, a -100.00% decrease from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024). COGT's quarterly revenue for Q4 2024 was $4.29M, a 100.00% increase from the previous quarter (Q3 2024), and a -23.19% decrease year-over-year (Q4 2023).

What is Cogent Biosciences’s revenue growth rate?

Cogent Biosciences's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was -100.00%.

What are Cogent Biosciences’s revenue streams?

Cogent Biosciences's revenue streams in c 19 are Preclinical Research And Clinical Development

What is Cogent Biosciences’s main source of revenue?

For the fiscal year ending Dec 19, the largest source of revenue of Cogent Biosciences was Preclinical Research And Clinical Development. This segment made a revenue of $25M, representing 100.00% of the company's total revenue.